drugset
drugset / Trial / NCT06226454

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

NCT06226454 ↗

Phase 1 Completed 39 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX-993 at different doses in healthy participants.

Timeline

Start
2024-01-04
Primary completion
2024-06-12
Completion
2024-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-993 Unknown — Oral

Indications

No indication recorded.